Oppenheimer reaffirmed their hold rating on shares of Acceleron Pharma (NASDAQ:XLRN) in a research note issued to investors on Monday, January 8th.
Several other analysts have also issued reports on the stock. BidaskClub upgraded shares of Acceleron Pharma from a hold rating to a buy rating in a research note on Wednesday, December 27th. HC Wainwright reissued a buy rating and issued a $62.00 price target on shares of Acceleron Pharma in a report on Monday, December 11th. Credit Suisse Group set a $51.00 price target on shares of Acceleron Pharma and gave the stock a buy rating in a report on Tuesday, November 14th. Royal Bank of Canada reaffirmed a hold rating on shares of Acceleron Pharma in a report on Thursday, November 2nd. Finally, ValuEngine downgraded shares of Acceleron Pharma from a hold rating to a sell rating in a report on Friday, October 6th. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and eleven have given a buy rating to the stock. Acceleron Pharma has a consensus rating of Hold and a consensus target price of $44.81.
Acceleron Pharma (NASDAQ XLRN) traded down $0.90 during trading hours on Monday, reaching $40.81. 205,253 shares of the company traded hands, compared to its average volume of 318,015. The firm has a market cap of $1,877.71 and a P/E ratio of -15.76. Acceleron Pharma has a twelve month low of $23.07 and a twelve month high of $46.93.
Acceleron Pharma (NASDAQ:XLRN) last released its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, beating the consensus estimate of ($0.67) by $0.02. The company had revenue of $3.00 million during the quarter, compared to analyst estimates of $3.52 million. Acceleron Pharma had a negative net margin of 759.34% and a negative return on equity of 40.70%. Acceleron Pharma’s revenue for the quarter was up .0% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.55) EPS. analysts predict that Acceleron Pharma will post -2.65 EPS for the current year.
In related news, CFO Kevin F. Mclaughlin sold 19,000 shares of the firm’s stock in a transaction on Thursday, January 4th. The stock was sold at an average price of $42.89, for a total value of $814,910.00. Following the completion of the sale, the chief financial officer now owns 45,300 shares of the company’s stock, valued at $1,942,917. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Jean George sold 105,122 shares of the firm’s stock in a transaction on Friday, December 15th. The stock was sold at an average price of $35.73, for a total value of $3,756,009.06. Following the completion of the sale, the director now directly owns 1,250 shares of the company’s stock, valued at approximately $44,662.50. The disclosure for this sale can be found here. In the last three months, insiders have sold 146,021 shares of company stock valued at $5,529,598. Insiders own 3.90% of the company’s stock.
Hedge funds have recently made changes to their positions in the stock. Quantbot Technologies LP lifted its position in Acceleron Pharma by 416.3% during the third quarter. Quantbot Technologies LP now owns 2,917 shares of the biopharmaceutical company’s stock valued at $108,000 after buying an additional 2,352 shares during the period. BNP Paribas Arbitrage SA lifted its position in Acceleron Pharma by 969.9% during the second quarter. BNP Paribas Arbitrage SA now owns 3,627 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 3,288 shares during the period. Public Employees Retirement Association of Colorado purchased a new position in Acceleron Pharma during the fourth quarter valued at $138,000. Oppenheimer & Co. Inc. purchased a new position in Acceleron Pharma during the third quarter valued at $225,000. Finally, PNC Financial Services Group Inc. lifted its position in Acceleron Pharma by 57.8% during the second quarter. PNC Financial Services Group Inc. now owns 8,460 shares of the biopharmaceutical company’s stock valued at $258,000 after buying an additional 3,100 shares during the period. 85.62% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: This story was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another publication, it was illegally stolen and republished in violation of U.S. & international trademark & copyright law. The correct version of this story can be viewed at https://www.dispatchtribunal.com/2018/02/02/acceleron-pharmas-xlrn-hold-rating-reiterated-at-oppenheimer.html.
Acceleron Pharma Company Profile
Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.
Receive News & Ratings for Acceleron Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma and related companies with MarketBeat.com's FREE daily email newsletter.